The Alternative Investment Market (AIM) of the London Stock Exchange has historically served as a critical incubator for high-growth healthcare technology and medical device companies, providing a unique environment where innovative small-to-mid-cap entities can access public capital while benefiting from a more flexible regulatory regime than the Main Market. As of March 2026, the sector is characterised by a profound transition. The intersection of the United Kingdom gover

The UK National Commission on the Regulation of AI in Healthcare has been established as a critical, non-statutory advisory body by the Medicines and Healthcare products Regulatory Agency (MHRA) to address the growing disparity between the rapid pace of artificial intelligence (AI) innovation and a legacy regulatory framework. Its mandate is to review existing regulations and provide a comprehensive set of recommendations for a new, rewritten rulebook for AI in healthcare, wh